Background: Angiotensin-converting enzyme 2 (ACE2) is a homologue of
such as angiotensin 1-7, in dogs with CHF (486.7 pg/mL; IQR, 214.2-1168) as compared to those with preclinical disease (41.0 pg/mL; IQR, 27.4-45.1; P < .0001) or control (11.4 pg/mL; IQR, 7.1-25.3; P = .01). Incubation of plasma samples from dogs with CHF with rhACE2 increased beneficial APs, such as angiotensin [1] [2] [3] [4] [5] [6] [7] [8] [9] (preincubation, 10.3 pg/mL; IQR, 4.4-37.2; postincubation, 2431 pg/mL; IQR, 1355-3037; P = .02), while simultaneously decreasing maladaptive APs, such as angiotensin II (preincubation, 53.4 pg/mL; IQR, 28.6-226.4; postincubation, 2.4 pg/mL; IQR, 0.50-5.8; P = .02).
Conclusions and Clinical Importance: Recognition of the ACE2 system expands the conventional view of the RAAS in the dog and represents an important potential therapeutic target.
K E Y W O R D S
angiotensin 1-7, angiotensin II, degenerative mitral valve disease, renin-angiotensin-aldosterone system
| INTRODUCTION
The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathophysiology of heart disease and heart failure in dogs. [1] [2] [3] [4] The traditional concept of the RAAS is as follows: cardiac disease, as well as treatments for cardiac disease, such as diuretics, decrease perfusion of the kidney, activating release of renin, which converts angiotensinogen to the 10-amino acid peptide, angiotensin I (AT1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] ). Subsequently, the dipeptidyl-carboxypeptidase, angiotensin-converting enzyme (ACE), cleaves 2 amino acids from the C-terminus of AT1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) to form the octapeptide, angiotensin II (AT2 [1] [2] [3] [4] [5] [6] [7] [8] ). Angiotensin II acts primarily through angiotensin receptor type 1 and causes potent vasoconstriction, sodium and water conservation, aldosterone release, and myocardial remodeling. 5 Thus, the traditional view of the RAAS is that of a linear and maladaptive pathological system that is overactive during heart failure and often suppressed using ACE inhibitors (ACEIs) and aldosterone antagonists. This understanding changed with the discovery of a homologue of ACE, called angiotensin-converting enzyme 2 (ACE2). 6, 7 Like ACE, ACE2 is a membrane-bound zinc metalloproteinase; the catalytic site of which is capable of binding various angiotensin peptides (APs), such as AT2 (1) (2) (3) (4) (5) (6) (7) (8) . However, ACE2 is a mono-carboxypeptidase and it removes only a single amino acid from the C-terminus of its catalytic substrate. 8, 9 For example, ACE2 acts on AT1(1-10) and AT2 (1) (2) (3) (4) (5) (6) (7) (8) to produce a 9-amino acid peptide called angiotensin 1-9 (Ang1-9) and a 7-amino acid peptide called angiotensin 1-7 (Ang1-7), respectively. 10 Despite being different by only 1 amino acid, the biological effects of Ang1-9 and Ang1-7 are opposite of those associated with AT2 (1) (2) (3) (4) (5) (6) (7) (8) . Specifically, Ang1-9 and Ang1-7 are vasodilatory, natriuretic, diuretic, antifibrotic, and antiremodeling. 9 These beneficial APs mediate the majority of their effects by binding to angiotensin receptor type 2 or an endogenous orphan Mas receptor (MasR), as opposed to binding to ATR1. 11, 12 It is now known 9, 13 that the ACE2 system provides an endogenous counterbalance to ACE and that an expanded view of the RAAS involves many different APs with structures differing by 1 to 5 amino acids. Thus, RAAS is considerably more complex than those traditionally viewed, and this discovery has uncovered a broad new set of molecules to explore, understand, and potentially modify in subjects with heart disease.
Very little is known about the ACE2 system and related APs in veterinary species. To the best of our knowledge, studies of ACE2 in dogs with naturally occurring heart disease are lacking. We sought to detect and describe the location of ACE2 immunoreactivity in the kidney and left ventricular (LV) myocardium to quantify the activity of plasma, kidney, and LV myocardial ACE2, to determine the equilibrium concentrations of 10 different circulating APs, and to determine the effect of recombinant human ACE2 on the relative amounts of beneficial versus maladaptive APs. Our hypotheses were that the evidence of ACE2 could be found in tissues and plasma of dogs, that equilibrium concentrations of RAAS APs would differ in dogs with heart disease versus healthy dogs, and recombinant human ACE2 (rhACE2)
can alter relative concentrations of APs.
| MATERIALS AND METHODS
The study protocol was reviewed and approved by the University of Pennsylvania Institutional Animal Care and Use Committee and informed owner consent was obtained.
| Angiotensin-converting enzyme 2 immunohistochemistry (IHC)
Cohorts of dogs that died or were euthanized for cardiac diseases and dogs that died from noncardiac reasons at the University of Pennsylvania were recruited. Sections of left kidney that included both cortical and medullary tissue and full thickness LV myocardial samples from the lateral wall of the ventricle just apical to the mid-point of the paraconal coronary artery were obtained within 60 minutes of death. The left atrium-to-aortic root ratio (LA:Ao) was calculated using measurements from the 2D right short axis. 15 Echocardiographic values were the average value of 3 measured beats. Healthy dogs that primarily were owned by staff and employees of the veterinary hospital were recruited as a control group and included dogs without a heart murmur or clinical signs suggestive of heart disease. Control dogs weighing >25 kg had a 2D echocardiogram performed to exclude the potential for occult dilated cardiomyopathy (DCM). Venipuncture was performed, and lithium heparinized plasma samples were obtained. Samples were stored at −80 C until batch analysis. Activity of ACE2 in heparinized plasma was measured using a fluorometric assay kit (#K897-100, Biovision Inc, Milpitas, California). The ACE2 activity results are reported in milliunits per mg protein (mU/mg). The assay has a lower detection limit of 0.4 mU. Additional details regarding the performance and validation of the assay are described in the Supporting Information.
| Tissue ACE2 activity
A cohort of dogs that died or were euthanized as a consequence of cardiac disease and dogs that died of noncardiac diseases were recruited to obtain kidney and LV myocardial samples as previously described.
Kidney and LV myocardium lysates were prepared by homogenizing approximately 100 μg tissue sections in ACE2 lysis buffer (Biovision Inc) using a disposable tissue homogenizer (#0254210, Fisher Thermo Scientific, Waltham, Massachusetts). Lysates were kept on ice for 10 minutes followed by gentle vortexing followed by another 5 minutes on ice. The tissue lysates then were centrifuged at 16 000g at 4 C for 10 minutes and the pellets discarded. Activity of ACE2 in tissue lysates was measured using the same fluorometric assay kit used to assay plasma ACE2 activity. The protein concentrations of the plasma and tissue lysates were measured using a bicinchoninic acid method and bovine serum albumin protein standard (#K813, Biovision Inc). 
|

| Statistical methods
Descriptive statistics for the various patient groups were generated.
Normality was tested using the Shapiro-Wilk test. Nonparametric tests were used if data were not normally distributed. Data that were below the lower limit of quantification for any particular assay were entered as a value equal to 0.5 times the lower limit of quantification as previously recommended. 21 The presence of any extreme outlying data points was identified by the Grubbs' test, which restricts potential removal to ≤1 data point from each data set. 22 Differences between 2 unpaired groups were tested using Wilcoxon rank sum or unpaired t tests. Differences across ≥3 groups were tested using Kruskal-Wallis or 1-way analysis of variance (ANOVA) and post hoc pairwise comparisons were performed using Dunn's test with correction for multiple comparisons or Bonferroni correction, respectively.
Box and whisker plots were constructed with the line representing the median value, the limits of the box representing the 25th and 75th percentiles, and the whiskers extending to the 5th and 95th
percentiles. Correlations among various patient demographic data, echocardiographic variables, and assay results were explored using Pearson correlation coefficient or Spearman rho and unadjusted P values.
Concentrations of APs before and after administration of rhACE2 were evaluated by Wilcoxon signed rank tests. Data are shown as median (interquartile range), unless otherwise specified. Statistical procedures were performed using statistical software (Prism 8 for OS X, GraphPad
Software Inc, La Jolla, California). Significance was defined as P < .05.
3 | RESULTS
| Immunohistochemistry
Tissues from 6 dogs were obtained including 3 control dogs euthanized for noncardiac disease and 3 dogs euthanized because of CHF related to end-stage DMVD. Control dogs did not have a heart murmur or any history or clinical signs of heart disease and included the following: 15-year-old female spayed mixed breed dog with a painful
Representative photomicrographs of anti-angiotensin-converting enzyme 2 (ACE2) immunolabeling from a 10-year-old male neutered French Bulldog that was euthanized secondary to upper airway obstruction (A-C), a 10-year-old female spayed mixed breed dog euthanized for severe congestive heart failure (CHF) because of degenerative mitral valve disease (DMVD) (D, E), and 10-year-old female spayed Chihuahua also euthanized for severe CHF due to DMVD (F). Figure 2 ). This result was consistent regardless of whether or not the outlier value was included in the analysis. No significant correlation was found between ACE2 activity and age (R 2 = .057, P = .34) or body weight (Spearman r = −.092, P = .72) in the healthy cohort. Figure 3 ). This result was the same regardless of whether or not the outlier value was included in the analysis. The ACE2 activity per milligram of protein in kidney tissue was approximately 250 to 500 times higher than circulating or LV myocardial ACE2 activity.
| Plasma ACE2 activity
| Kidney and myocardial ACE2 activity
Assays for circulating and tissue ACE2 activity were performed on average 10 days (range, 3-29) after the date of sample collection.
T (11) (12) (13) (14) .0001
Body weight (kg) 11.1 (9.1-24. The signalment and treatments at the time of sampling are presented in Table 2 . Differences in concentrations across and between groups were detected for a number of APs, including AT1(1-10), Ang1-7, Ang1-9, Ang2-10, Ang2-7, and Ang3-7 (Table 3 ). In general, the concentration of each of these APs was highest in dogs in stage C, intermediate in stage B1 or B2, and lowest in healthy dogs (Figure 4) .
A global overview of the expanded RAAS identified large differences in the overall activation and relative amounts of APs across patient groups ( Figure 5 ). Of note, median AT1(1-10) was >43 and 17 times higher in stage C than healthy and stage B2 dogs, respectively.
Median Ang1-7 in stage C was > 43 and 11 times higher than in healthy and stage B2 dogs, respectively, and median Ang1-9 in stage C was >5 times higher than in both healthy and stage B1 or B2 dogs.
No differences across groups were found for AT2(1-8), AT3(2-8), AT4 was approximately 27 and 12 times higher than that in healthy dogs or dogs in stage B2, respectively ( Table 3 ). The median ACE surr also was significantly different across patient groups ( Figure 6 ). The median ACE surr in stage C was 16 to 20 times lower than that in healthy dogs or dogs in stages B1 or B2 (Table 3) 
| DISCUSSION
The discovery of ACE2 and its related APs (Figure 8 ) is a subject of intense study in humans with heart disease, [23] [24] [25] [26] [27] and to our knowledge, our study is the first to provide an expanded view of RAAS in dogs with heart disease. Our results identify ACE2 immunolabeling and activity in canine LV myocardium. Previous reports in rats 28 and humans 6,28 indicated similar findings, suggesting an important role for ACE2 in cardiac function. Strong immunolabeling and a high degree of ACE2 activity also was found in the renal tubular epithelium, consistent with previous studies in dogs, 29 mice, 30 and humans. 6, 7 Our results indicate that the ACE2 system is regulated differently in dogs with heart disease as compared to healthy dogs. First, plasma ACE2 activity was significantly increased in dogs with CHF, similar to previous reports in human patients with heart disease. In 1 such study, 31 serum ACE2 activity was significantly increased secondary to ischemic and nonischemic heart disease and was independent of medications or comorbidities. In other studies, [32] [33] [34] portions of the cell membrane, which then are released into the surrounding extracellular space. 33, 35, 36 The resultant ectosomes contain ACE2 as well as the immediate surrounding extracellular environment and enter the circulation or urine. This process is described as ectodomain shedding. 36, 37 Previous studies 35 indicate that shedding of ACE2 is more frequent than shedding of ACE, which also is highly membrane bound, and that AT2(1-8), tumor necrosis factor, interleukin 1β, and disintegrin metalloproteases are potent stimuli for ACE2 shedding in mice and humans. [37] [38] [39] Thus, the increase in circulating ACE2 might represent pathological displacement of ACE2 from its normal tissue membrane location, mediated in part by a feedback loop in which various substances decrease the activity of its negative regulator. 39 As a result, circulating ACE2, which is removed from its normal location and ideal environment, is hypothesized to represent wasted or ineffective ACE2. 31, 39 In our study, activity of circulating ACE2 normalized to protein amount was approximately 100-fold less than activity of kidney ACE2, which supports this hypothesis. Our results, however, also indicated that both the kidney and LV ACE2 activity were not significantly different in dogs with CHF as compared to healthy dogs, suggesting that ACE2 shedding was not an important factor in the total extent of tissue-bound ACE2 activity, but a loss of tissue ACE2 into the circulation would tend to decrease the overall compensatory potential of ACE2. 31, 33, 39 Further elucidation of a seemingly complex relationship between circulating and tissue ACE2 is needed.
A second important finding of our study is the relationships and relative concentrations of various APs within the expanded RAAS, which provides insight into the pathophysiology of disease. Beginning at the first portion of RAAS (Figure 8 ), our results indicate that heart disease in the dog is associated with increased plasma renin activity. This finding is consistent with previous reports in dogs 1, 40 and leads to higher concentrations of AT1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . In stages B1 and B2, downstream activation of RAAS and generation of AT2 (1-8) T A B L E 2 Signalment, echocardiographic, and treatment data from 34 dogs undergoing analysis of equilibrium concentrations of renin angiotensin aldosterone system angiotensin peptides. Data shown as mean (SD) or median (interquartile range) unless otherwise specified. Ang2-10, Ang1-9, and Ang1-7, respectively. 12 The actions of these APs, and in particular Ang1-9 and Ang1-7, have been studied in a variety of species, including humans, dogs, and rats, and include vasodilatation, natriuresis, activation of nitric oxide, antagonism of T A B L E 3 Median and interquartile value of plasma equilibrium concentrations of angiotensin peptides and surrogate measures of plasma renin activity (PRA-surrogate) and angiotensin-converting enzyme (ACE-surrogate) activity in healthy dogs and dogs with heart disease. See text for description of the modified clinical staging system pg/mL 2.9-6.6 6.6-2627. F I G U R E 4 Equilibrium concentrations of angiotensin peptides (APs) of the reninangiotensin-aldosterone system (RAAS) in control dogs (CTL) and dogs with stage B1, B2, and C heart disease. Ang1-5, angiotensin 1-5; Ang1-7, angiotensin 1-7; Ang1-9, angiotensin 1-9; Ang 2-7, angiotensin 2-7, Ang2-10, angiotensin 2-10; Ang3-7, angiotensin 3-7; AT1(1-10), angiotensin I; AT2(1-8), angiotensin II; AT3(2-8), angiotensin III; AT4(3-8), angiotensin IV. See text for description of the modified clinical staging system. *P < .05; **P < .01; ***P < .001; ****P < .0001 
. [52] [53] [54] In our study, equilibrium concentrations of AT3 (2) (3) (4) (5) (6) (7) (8) and AT4 (3) (4) (5) (6) (7) (8) in dogs with heart disease were not significantly differ- A previous study 47 reported that Ang2-10 is vasodilatory and antiproliferative whereas another study 55 reported that Ang2-10 was vasoconstrictive, but likely only after conversion to AT3 (2) (3) (4) (5) (6) (7) (8) . As for the remaining APs, in humans, Ang(2-7) induces mild vasoconstriction, 56 Ang(3-7) is thought to be a centrally acting vasoconstrictor, 57 and Ang1-5 binds MasR and causes vasodilatation and increased natriuretic peptide release. 58 Thus, results of RAAS AP equilibrium analysis in dogs with CHF receiving ACEI indicated an increase in beneficial APs including Ang1-9, Ang1-7, and Ang2-10; no change in beneficial APs including AT4(3-8) and Ang1-5; an increase in maladaptive APs, including Ang2-7 and Ang3-7; and no change in maladaptive APs including AT2(1-8) and AT3(2-8). These data offer F I G U R E 5 Equilibrium concentrations of angiotensin peptides (APs) and angiotensin converting enzyme (ACE) and angiotensin-convertingenzyme 2 (ACE2) pathways within a broader view of the renin-angiotensin-aldosterone system (RAAS) permits evaluation of the relative concentration and relationship between the various APs. The sizes of the circles are proportional to the median equilibrium concentration (pg/mL) of each AP. See text for description of the modified clinical staging system. AmP, aminopeptidase; DAP, aspartyl aminopeptidase; NEP, neutral endopeptidase. Other abbreviations same as in Figure 4 P F I G U R E 6 Surrogate measures of plasma renin activity (PRA surr ) and angiotensin converting enzyme (ACE) activity (ACE surr ) in healthy control (CTL) and dogs with stage B1, B2, and C heart disease. See text for description of the modified clinical staging system. *P < .05; **P < .01; ***P < .001; ****P < .0001 insight into the pathophysiology of disease and suggest novel treatment approaches as discussed below.
A third important finding of our study is the ability to shift the balance of APs within the RAAS using rhACE2. The counter regulatory role of ACE2 on the maladaptive effects of ACE and AT2 (1) (2) (3) (4) (5) (6) (7) (8) make ACE2 and its related APs attractive targets for pharmacotherapy. 23, [25] [26] [27] 45, [59] [60] [61] Treatment with exogenous ACE2 is particularly interesting in light of the fact that the affinity of ACE2 to cleave AT2
(1-8) into beneficial Ang1-7 is 12-fold greater than the affinity of ACE to cleave AT1(1-10) to AT2(1-8), 62 suggesting that exogenous ACE2 or ACE2 activators would be capable of converting even large amounts of AT2 (1) (2) (3) (4) (5) (6) (7) (8) . In our study, incubation of plasma samples with rhACE2 from dogs with stage B2 or stage C heart disease resulted in significantly higher equilibrium concentrations of beneficial APs, including Ang1-9, Ang1-7, and Ang1-5, while simultaneously decreasing the concentration of maladaptive APs, including AT1(1-10) and AT2 (1) (2) (3) (4) (5) (6) (7) (8) [32] [33] [34] determined that increased ACE2 activity was associated with poor outcome, in a study involving patients after intensive treatment for acute CHF, 65 In summary, our results provide novel information about the presence, distribution, activity, and equilibrium concentrations of components of the ACE2 system and an expanded view of the RAAS in dogs with heart disease. Activity of both the traditional and ACE2-related components of RAAS was significantly different in affected dogs, and potential new targets for treatment were identified. Our study provided proof of concept that rhACE2 could modify RAAS in such a manner that would increase newly described beneficial APs while suppressing maladaptive APs. Consideration of an expanded RAAS that includes ACE2 and related APs opens new opportunities to understand and treat heart disease in dogs.
